Compare GTY & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | VCEL |
|---|---|---|
| Founded | 1955 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1998 | 1996 |
| Metric | GTY | VCEL |
|---|---|---|
| Price | $28.39 | $58.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $33.86 | ★ $63.57 |
| AVG Volume (30 Days) | 490.7K | ★ 803.8K |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.97% | N/A |
| EPS Growth | 8.00 | ★ 60.00 |
| EPS | ★ 1.18 | 0.19 |
| Revenue | $221,727,000.00 | ★ $276,259,000.00 |
| Revenue This Year | $8.60 | $24.98 |
| Revenue Next Year | $10.70 | $15.37 |
| P/E Ratio | ★ $24.39 | $311.28 |
| Revenue Growth | 9.02 | ★ 16.45 |
| 52 Week Low | $27.08 | $28.95 |
| 52 Week High | $36.83 | $59.72 |
| Indicator | GTY | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 81.42 |
| Support Level | $27.30 | $31.94 |
| Resistance Level | $28.75 | N/A |
| Average True Range (ATR) | 0.52 | 2.57 |
| MACD | 0.14 | 1.95 |
| Stochastic Oscillator | 47.93 | 95.32 |
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.